Trial Information
Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Inclusion Criteria:
- ≥ 18 years old
- ECOG score of 0, 1, or 2
- Histologically confirmed diagnosis of non-small cell lung cancer
Exclusion Criteria:
Laboratory values demonstrating inadequate function of the following:
- Bone marrow
- Kidneys
- Liver
and
- Peripheral neuropathy Grade 2 or higher
- Greater than 2 prior chemotherapy regimens
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Dose limiting toxicities of MGd when administered concurrently with docetaxel and cisplatin
Authority:
United States: Food and Drug Administration
Study ID:
PCYC-0220
NCT ID:
NCT00102505
Start Date:
November 2004
Completion Date:
Related Keywords:
- Non-Small-Cell Lung Carcinoma
- Carcinoma, Bronchogenic
- Non-Small Cell Lung Cancer
- Lung Cancer
- Metastatic lung cancer
- Inoperable lung cancer
- Advanced lung cancer
- Large-cell lung cancer
- Adenocarcinoma, lung
- Squamous cell carcinoma, lung
- Squamous cell lung cancer
- Large cell carcinoma, lung
- Bronchogenic
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
The University of Texas MD Anderson Cancer Center |
Houston, Texas 77030-4009 |